Literature DB >> 18560388

Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.

Scott R Plotkin1, Marybeth A Singh, Caroline C O'Donnell, Gordon J Harris, Andrea I McClatchey, Chris Halpin.   

Abstract

BACKGROUND: A 48-year-old man presented to a neurologist with complaints of bilateral hearing loss and tinnitus. The patient was a member of a large family affected by neurofibromatosis type 2 and first noted hearing loss 10 years before presentation. INVESTIGATIONS: Medical and neurological examination, MRI scan of the brain and spinal cord, pure-tone audiometry, NU-6 monosyllabic word test with phoneme scoring, City University of New York topic-related sentences test, noise/voice test of minimal auditory capability battery. DIAGNOSIS: Progressive neurofibromatosis-type-2-related vestibular schwannomas. MANAGEMENT: Annual cranial MRI and audiology, surgical resection of right vestibular schwannoma, high-power behind-the-ear hearing aid, erlotinib therapy for progressive left vestibular schwannoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18560388     DOI: 10.1038/ncponc1157

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  20 in total

1.  Temporal bone histopathology in neurofibromatosis type 2.

Authors:  Sung-Il Nam; Fred H Linthicum; Saumil N Merchant
Journal:  Laryngoscope       Date:  2011-06-10       Impact factor: 3.325

2.  Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.

Authors:  Vivek Subbiah; John Slopis; David S Hong; Leena M Ketonen; Jackson Hamilton; Ian E McCutcheon; Razelle Kurzrock
Journal:  J Clin Oncol       Date:  2011-12-27       Impact factor: 44.544

3.  Auditory rehabilitation of patients with neurofibromatosis Type 2 by using cochlear implants.

Authors:  Pamela C Roehm; Jon Mallen-St Clair; Daniel Jethanamest; John G Golfinos; William Shapiro; Susan Waltzman; J Thomas Roland
Journal:  J Neurosurg       Date:  2011-07-15       Impact factor: 5.115

4.  Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.

Authors:  Scott R Plotkin; Chris Halpin; Michael J McKenna; Jay S Loeffler; Tracy T Batchelor; Fred G Barker
Journal:  Otol Neurotol       Date:  2010-09       Impact factor: 2.311

5.  Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2.

Authors:  Matthieu Peyre; Stephane Goutagny; Sandrine Imbeaud; Alexis Bozorg-Grayeli; Michele Felce; Olivier Sterkers; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2011-07-28       Impact factor: 12.300

6.  MicroRNA-21 overexpression contributes to vestibular schwannoma cell proliferation and survival.

Authors:  Joseph A Cioffi; Wei Ying Yue; Sabrina Mendolia-Loffredo; Kameron R Hansen; P Ashley Wackym; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2010-12       Impact factor: 2.311

7.  An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.

Authors:  Dina S Stepanova; Galina Semenova; Yin-Ming Kuo; Andrew J Andrews; Sylwia Ammoun; C Oliver Hanemann; Jonathan Chernoff
Journal:  Cancer Res       Date:  2017-07-20       Impact factor: 12.701

8.  Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter.

Authors:  S Prabhakar; G J Brenner; B Sung; S M Messerli; J Mao; M Sena-Esteves; A Stemmer-Rachamimov; B Tannous; X O Breakefield
Journal:  Cancer Gene Ther       Date:  2009-10-16       Impact factor: 5.987

Review 9.  Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Authors:  Scott R Plotkin; Chris Halpin; Jaishri O Blakeley; William H Slattery; D Bradley Welling; Susan M Chang; Jay S Loeffler; Gordon J Harris; A Gregory Sorensen; Michael J McKenna; Fred G Barker
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

Review 10.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.